CPI is undertaking preliminary market engagement to inform a potential future procurement relating to a novel pharmaceutical manufacturing method. The purpose of this engagement is to understand market capabilities, capacity, innovations, indicative costs, and potential delivery timelines prior to finalising our procurement strategy.
This notice does not constitute a call for competition or a commitment to proceed with a tender. It is an information gathering exercise only.
CENTRE FOR PROCESS INNOVATION LIMITEDNorth East7 May 2026WAC-579533
This tender seeks to engage a qualified service provider to perform cell based, in vitro potency assays for the quantification of both RNA (drug substance) and RNA-LNP (Lipid Nanoparticle) (drug product) activity. The assays will be used to evaluate the biological functionality of RNA-LNP formulations, ensuring consistency and efficacy during production.
CENTRE FOR PROCESS INNOVATION LIMITEDNorth East15 May 2026WAC-583000
This tender seeks to engage a qualified service provider to perform cell based, in vitro potency assays for the quantification of both RNA (drug substance) and RNA-LNP (Lipid Nanoparticle) (drug product) activity. The assays will be used to evaluate the biological functionality of RNA-LNP formulations, ensuring consistency and efficacy during production.
CENTRE FOR PROCESS INNOVATION LIMITEDNorth East15 May 2026WAC-582995